Argenx (ARGX) is expanding its partnership with Fujifilm Biotechnologies to support local-for-local supply of medicines in the US, Fujifilm said Thursday.

The company said argenx will benefit from its network that provides local-for-local supply, manufacturing close to its patients.

Fujifilm said argenx is the first announced tenant at phase II expansion at its North Carolina site, where it will start manufacturing argenx's drug substance for efgartigimod in 2028.

Efgartigimod is approved worldwide for the treatment of adults with generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, which are chronic autoimmune neuromuscular diseases, Fujifilm said.

Price: 733.52, Change: -0.83, Percent Change: -0.11